Randomized controlled trial evaluating the temporal effects of high-intensity exercise on learning, short-term and long-term memory, and prospective memory

2017 ◽  
Vol 46 (10) ◽  
pp. 2557-2564 ◽  
Author(s):  
Emily Frith ◽  
Eveleen Sng ◽  
Paul D. Loprinzi
Keyword(s):  
Randomized Controlled Trial ◽  
Prospective Memory ◽  
High Intensity ◽  
Controlled Trial ◽  
High Intensity Exercise ◽  
Long Term Memory ◽  
Short Term ◽  
Term Memory ◽  
Randomized Controlled

Effects of combining retrieval practice and tDCS over long-term memory: A randomized controlled trial

2021 ◽  
pp. 105807
Author(s):  
Beatriz Araújo Cavendish ◽  
Marcos Felipe Rodrigues de Lima ◽  
Lara Perícoli ◽  
Luciano Grüdtner Buratto
Keyword(s):  
Randomized Controlled Trial ◽  
Retrieval Practice ◽  
Controlled Trial ◽  
Long Term Memory ◽  
Term Memory ◽  
Randomized Controlled

scholarly journals Is a long-term high-intensity exercise program effective and safe in patients with rheumatoid arthritis?: Results of a randomized controlled trial

2003 ◽  
Vol 48 (9) ◽  
pp. 2415-2424 ◽  
Author(s):  
Zuzana de Jong ◽  
Marten Munneke ◽  
Aeilko H. Zwinderman ◽  
Herman M. Kroon ◽  
Annemarie Jansen ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Randomized Controlled Trial ◽  
High Intensity ◽  
Controlled Trial ◽  
Exercise Program ◽  
High Intensity Exercise ◽  
Randomized Controlled

scholarly journals Slowing of bone loss in patients with rheumatoid arthritis by long-term high-intensity exercise: Results of a randomized, controlled trial

2004 ◽  
Vol 50 (4) ◽  
pp. 1066-1076 ◽  
Author(s):  
Zuzana de Jong ◽  
Marten Munneke ◽  
Willem F. Lems ◽  
Aeilko H. Zwinderman ◽  
Herman M. Kroon ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Randomized Controlled Trial ◽  
Bone Loss ◽  
High Intensity ◽  
Controlled Trial ◽  
High Intensity Exercise ◽  
Randomized Controlled

scholarly journals Endothelial Dysfunction, Atherosclerosis, and Increase of von Willebrand Factor and Factor VIII: A Randomized Controlled Trial in Swine

2021 ◽  
Author(s):  
Ferdows Atiq ◽  
Jens van de Wouw ◽  
Oana Sorop ◽  
Ilkka Heinonen ◽  
Moniek P. M. de Maat ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Randomized Controlled Trial ◽  
Endothelial Dysfunction ◽  
Controlled Trial ◽  
Short Term ◽  
Randomized Controlled ◽  
Von Willebrand ◽  
Willebrand Factor

AbstractIt is well known that high von Willebrand factor (VWF) and factor VIII (FVIII) levels are associated with an increased risk of cardiovascular disease. It is still debated whether VWF and FVIII are biomarkers of endothelial dysfunction and atherosclerosis or whether they have a direct causative role. Therefore, we aimed to unravel the pathophysiological pathways of increased VWF and FVIII levels associated with cardiovascular risk factors. First, we performed a randomized controlled trial in 34 Göttingen miniswine. Diabetes mellitus (DM) was induced with streptozotocin and hypercholesterolemia (HC) via a high-fat diet in 18 swine (DM + HC), while 16 healthy swine served as controls. After 5 months of follow-up, FVIII activity (FVIII:C) was significantly higher in DM + HC swine (5.85 IU/mL [5.00–6.81]) compared with controls (4.57 [3.76–5.40], p = 0.010), whereas VWF antigen (VWF:Ag) was similar (respectively 0.34 IU/mL [0.28–0.39] vs. 0.34 [0.31–0.38], p = 0.644). DM + HC swine had no endothelial dysfunction or atherosclerosis during this short-term follow-up. Subsequently, we performed a long-term (15 months) longitudinal cohort study in 10 Landrace–Yorkshire swine, in five of which HC and in five combined DM + HC were induced. VWF:Ag was higher at 15 months compared with 9 months in HC (0.37 [0.32–0.42] vs. 0.27 [0.23–0.40], p = 0.042) and DM + HC (0.33 [0.32–0.37] vs. 0.25 [0.24–0.33], p = 0.042). Both long-term groups had endothelial dysfunction compared with controls and atherosclerosis after 15 months. In conclusion, short-term hyperglycemia and dyslipidemia increase FVIII, independent of VWF. Long-term DM and HC increase VWF via endothelial dysfunction and atherosclerosis. Therefore, VWF seems to be a biomarker for advanced cardiovascular disease.

Sign in / Sign up

Export Citation Format

Share Document